Traducción en proceso. Mostrando versión en inglés.

Ontex shares fall as 2026 guidance disappoints amid weak Q4 results

ArchivadoVerificado|4 artículos|2 fuentes|1 bloques

Detectado: Actualizado: Analizado:

Finanzas Resultados

Hechos Reportados

Datos observables compartidos por todas las narrativas

•Ontex reported weak fourth-quarter results.
•Ontex issued 2026 guidance that disappointed investors.
•DexCom beat Q4 expectations and provided 2026 revenue guidance in line with consensus.
•Baxter missed Q4 earnings estimates and lowered its 2026 EPS guidance.

Qué Podría Pasar Si...

▸If Ontex revises its 2026 guidance upward in future updates investor confidence in Ontex shares may improve, potentially stabilizing or increasing its stock price.

Inicia sesión para ver todos los escenarios y señales.

Actores Clave

Instrumentos

📈Baxter shares 📈Ontex shares

Organizaciones

🏛Baxter 🏛Ontex

Cobertura por Fuentes

FINANCE

4 artículos

Más cobertura relacionada

Más sobre Baxter shares
Más sobre Ontex shares
Más sobre Baxter
Más sobre Ontex

Señales

Single-block coverageLow source diversity

Eventos Relacionados

▸Earnings call transcript: Tower Semiconductor Q4 2025 beats EPS forecast, stock risesArchivado ▸Globus Medical raises 2026 EPS guidance after record Q4 resultsArchivado ▸Huntsman Shares Fall After Q4 Earnings Miss EstimatesArchivado ▸Sun quarterly profit beats Wall Street forecastsArchivado ▸Earnings call transcript: LKQ’s Q4 2025 results miss EPS expectations, stock dips

Fuentes (4)

FINANCESeeking Alpha - Market NewsDexCom Q4 results beat on both lines; 2026 revenue guidance includes consensus FINANCEInvesting.com - NewsJFrog shares tumble despite earnings beat and strong guidance FINANCESeeking Alpha - Market NewsBaxter slips following Q4 bottom line miss, weak 2026 EPS guidance FINANCE

Ontex experienced a decline in its share price following the release of its fourth-quarter results, which were weaker than expected. The company also provided 2026 guidance that fell short of market expectations, contributing to investor disappointment. This performance contrasts with other companies reporting on the same day, such as DexCom, which beat Q4 estimates and met revenue guidance, and JFrog, which posted strong earnings and guidance despite a share price drop. Baxter also reported weaker Q4 results and lowered its 2026 EPS guidance, indicating a challenging environment for some firms in this reporting period.